These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 23512266)
1. Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. Soda Y; Myskiw C; Rommel A; Verma IM J Mol Med (Berl); 2013 Apr; 91(4):439-48. PubMed ID: 23512266 [TBL] [Abstract][Full Text] [Related]
2. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Miletic H; Niclou SP; Johansson M; Bjerkvig R Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067 [TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630 [TBL] [Abstract][Full Text] [Related]
4. Recruitment of bone marrow derived cells during anti-angiogenic therapy in GBM: the potential of combination strategies. Boer JC; Walenkamp AM; den Dunnen WF Crit Rev Oncol Hematol; 2014 Oct; 92(1):38-48. PubMed ID: 24933160 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme. Onishi M; Kurozumi K; Ichikawa T; Date I Neurol Med Chir (Tokyo); 2013; 53(11):755-63. PubMed ID: 24162241 [TBL] [Abstract][Full Text] [Related]
6. Angiogenesis in glioblastoma multiforme: navigating the maze. Linkous AG; Yazlovitskaya EM Anticancer Agents Med Chem; 2011 Oct; 11(8):712-8. PubMed ID: 21707499 [TBL] [Abstract][Full Text] [Related]
7. Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration. Bazan NG; Reid MM; Flores VAC; Gallo JE; Lewis W; Belayev L Cancer Metastasis Rev; 2021 Sep; 40(3):643-647. PubMed ID: 34519960 [TBL] [Abstract][Full Text] [Related]
14. Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme. Kang W; Kim SH; Cho HJ; Jin J; Lee J; Joo KM; Nam DH Oncotarget; 2015 Sep; 6(29):27239-51. PubMed ID: 26336988 [TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic therapies in the management of glioblastoma. Schulte JD; Aghi MK; Taylor JW Chin Clin Oncol; 2021 Aug; 10(4):37. PubMed ID: 32389001 [TBL] [Abstract][Full Text] [Related]
16. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of VEGF in the treatment of glioblastoma. Robles Irizarry L; Hambardzumyan D; Nakano I; Gladson CL; Ahluwalia MS Expert Opin Ther Targets; 2012 Oct; 16(10):973-84. PubMed ID: 22876981 [TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648 [TBL] [Abstract][Full Text] [Related]
19. New Directions in Anti-Angiogenic Therapy for Glioblastoma. Wang N; Jain RK; Batchelor TT Neurotherapeutics; 2017 Apr; 14(2):321-332. PubMed ID: 28083806 [TBL] [Abstract][Full Text] [Related]
20. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma. Winkler F; Osswald M; Wick W Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]